Relx (LON:REL)‘s stock had its “hold” rating reaffirmed by Deutsche Bank in a research note issued on Friday, ThisIsMoney.Co.Uk reports.
Several other research analysts also recently weighed in on the company. JPMorgan Chase & Co. set a $195.00 price target on bluebird bio and gave the stock a “buy” rating in a research note on Friday, May 17th. UBS Group set a $54.00 price target on Westlake Chemical and gave the stock a “sell” rating in a research note on Tuesday, July 2nd. Finally, Goldman Sachs Group upgraded Las Vegas Sands to a “buy” rating in a research note on Tuesday, June 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Relx currently has a consensus rating of “Buy” and a consensus price target of GBX 1,821.50 ($23.80).
REL stock opened at GBX 1,939.50 ($25.34) on Friday. The company has a debt-to-equity ratio of 270.50, a current ratio of 0.44 and a quick ratio of 0.36. The company has a market cap of $37.78 billion and a P/E ratio of 27.16. Relx has a fifty-two week low of GBX 1,466.50 ($19.16) and a fifty-two week high of GBX 1,982.50 ($25.90). The business’s fifty day moving average price is GBX 1,898.85.
In other news, insider Henry Udow sold 50,831 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of GBX 1,759 ($22.98), for a total transaction of £894,117.29 ($1,168,322.61).
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Read More: What is the strike price in options trading?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.